CDN1163
CDN1163 has been studied in 1 paper since 2020: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Dec 22, 2020: “Restoration of Sarcoplasmic Reticulum Ca²⁺ ATPase (SERCA) Activity Prevents Age-Related Muscle Atrophy and Weakness in Mice”.
None of its findings points the other way.
- 1 lab in 1 country
- Funders: American Federation for Aging Research and 2 more
- Animals1
What did studies of CDN1163 find?
3Studies of CDN1163 measured 3 outcomes; the most studied are mitochondrial reactive oxygen species (1 study), muscle strength (1) and SERCA (1).
Mitochondrial reactive oxygen species
downin mice1
1 study
Mitochondrial reactive oxygen species
downin mice1
CDN1163 decreases mitochondrial reactive oxygen species in mice.
“CDN1163 administered by intra-peritoneal injection also prevented the increase in mitochondrial ROS production in gastrocnemius muscles of aged mice”
Animalsaginggastrocnemius muscle10 monthsmales
International journal of molecular sciences
Muscle strength
upin mice1
1 study
Muscle strength
upin mice1
CDN1163 improves muscle strength in mice (9% mass and 11% force reductions reversed).
“Reductions in gastrocnemius mass (9%) and in vitro specific force generation in extensor digitorum longus muscle (11%) in 26 versus 16-month-old wild-type mice were also reversed by CDN1163”
Animalsaging, 26-month-old miceskeletal muscle10 monthsmales
International journal of molecular sciences
SERCA
upin mice1+41% reduction prevented
1 study
SERCA
upin mice1+41% reduction prevented
CDN1163 increases SERCA in mice (41% reduction prevented).
“maximal SERCA activity was reduced 41% in gastrocnemius muscle in vehicle-treated mice but maintained in old CDN1163 treated mice”
Animalsaging, 26-month-old micegastrocnemius muscle10 monthsmales
International journal of molecular sciences